Cross-Business Integration by the Life Sciences Strategy Headquarters and Life Sciences Business Division
First written in FY2021. 2 of 3 entries say "Advanced", first in FY2022. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「In the life sciences business, the Company’s U.S. subsidiary FUJIFILM Cellular Dynamics, Inc. and Opsis Therapeutics, LLC agreed to grant BlueRock Therapeutics LP, a subsidiary of major pharmaceutical company Bayer AG, a licence for the development and commercialisation of treatments for retinal diseases using iPS cells.」
The company is advancing the cross-business deployment of its life sciences strategy through licensing of iPS cell technology and the recognition of one-time licensing revenue. - FY2022AdvancedAnnual report
「In February 2022, the company launched LS-CVC, its corporate venture capital arm for the life sciences field. It has established an investment framework of ¥7 billion over the five years through 2026, targeting biotechnology startups worldwide with advanced technologies and other capabilities.」
The cross-business initiatives of the Life Science Strategy Headquarters have been given concrete form through the launch of LS-CVC and the establishment of a ¥7 billion investment framework through 2026. - FY2021First statedAnnual report
「On 1 April 2021, the company established the Life Science Strategy Headquarters to formulate and implement overall strategy, including business portfolio management, M&A and alliances, technology and R&D, and to lead related businesses. It also established the Life Science Business Division to strengthen drug discovery support businesses by integrating the regenerative medicine business involving cells and culture media with the reagent business of the fine chemicals business.」
On 1 April 2021, the company newly established a cross-business strategy headquarters and business division covering regenerative medicine, culture media and reagents, drug discovery support, pharmaceuticals and other areas, creating a structure to jointly advance portfolio management, M&A and alliances, and technology and R&D for the first time.